697 related articles for article (PubMed ID: 28366764)
1. In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models.
Yin C; Zhang T; Qu X; Zhang Y; Putatunda R; Xiao X; Li F; Xiao W; Zhao H; Dai S; Qin X; Mo X; Young WB; Khalili K; Hu W
Mol Ther; 2017 May; 25(5):1168-1186. PubMed ID: 28366764
[TBL] [Abstract][Full Text] [Related]
2. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
3. Divergent susceptibilities to AAV-SaCas9-gRNA vector-mediated genome-editing in a single-cell-derived cell population.
Morsy SG; Tonne JM; Zhu Y; Lu B; Budzik K; Krempski JW; Ali SA; El-Feky MA; Ikeda Y
BMC Res Notes; 2017 Dec; 10(1):720. PubMed ID: 29221488
[TBL] [Abstract][Full Text] [Related]
4. Genome scale screening identification of SaCas9/gRNAs for targeting HIV-1 provirus and suppression of HIV-1 infection.
Wang Q; Liu S; Liu Z; Ke Z; Li C; Yu X; Chen S; Guo D
Virus Res; 2018 May; 250():21-30. PubMed ID: 29625148
[TBL] [Abstract][Full Text] [Related]
5. Delivering SaCas9 mRNA by lentivirus-like bionanoparticles for transient expression and efficient genome editing.
Lu B; Javidi-Parsijani P; Makani V; Mehraein-Ghomi F; Sarhan WM; Sun D; Yoo KW; Atala ZP; Lyu P; Atala A
Nucleic Acids Res; 2019 May; 47(8):e44. PubMed ID: 30759231
[TBL] [Abstract][Full Text] [Related]
6. Adeno-Associated Vector-Delivered CRISPR/
Helfer-Hungerbuehler AK; Shah J; Meili T; Boenzli E; Li P; Hofmann-Lehmann R
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452500
[TBL] [Abstract][Full Text] [Related]
7. In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice.
El Refaey M; Xu L; Gao Y; Canan BD; Adesanya TMA; Warner SC; Akagi K; Symer DE; Mohler PJ; Ma J; Janssen PML; Han R
Circ Res; 2017 Sep; 121(8):923-929. PubMed ID: 28790199
[TBL] [Abstract][Full Text] [Related]
8. Broad-Spectrum and Personalized Guide RNAs for CRISPR/Cas9 HIV-1 Therapeutics.
Dampier W; Sullivan NT; Mell JC; Pirrone V; Ehrlich GD; Chung CH; Allen AG; DeSimone M; Zhong W; Kercher K; Passic S; Williams JW; Szep Z; Khalili K; Jacobson JM; Nonnemacher MR; Wigdahl B
AIDS Res Hum Retroviruses; 2018 Nov; 34(11):950-960. PubMed ID: 29968495
[TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas9 Ablation of Integrated HIV-1 Accumulates Proviral DNA Circles with Reformed Long Terminal Repeats.
Lai M; Maori E; Quaranta P; Matteoli G; Maggi F; Sgarbanti M; Crucitta S; Pacini S; Turriziani O; Antonelli G; Heeney JL; Freer G; Pistello M
J Virol; 2021 Nov; 95(23):e0135821. PubMed ID: 34549986
[TBL] [Abstract][Full Text] [Related]
10. CRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination.
Herskovitz J; Hasan M; Patel M; Blomberg WR; Cohen JD; Machhi J; Shahjin F; Mosley RL; McMillan J; Kevadiya BD; Gendelman HE
EBioMedicine; 2021 Nov; 73():103678. PubMed ID: 34774454
[TBL] [Abstract][Full Text] [Related]
11. Promoter Orientation within an AAV-CRISPR Vector Affects Cas9 Expression and Gene Editing Efficiency.
Fry LE; Peddle CF; Stevanovic M; Barnard AR; McClements ME; MacLaren RE
CRISPR J; 2020 Aug; 3(4):276-283. PubMed ID: 32833533
[TBL] [Abstract][Full Text] [Related]
12. In Vivo Ryr2 Editing Corrects Catecholaminergic Polymorphic Ventricular Tachycardia.
Pan X; Philippen L; Lahiri SK; Lee C; Park SH; Word TA; Li N; Jarrett KE; Gupta R; Reynolds JO; Lin J; Bao G; Lagor WR; Wehrens XHT
Circ Res; 2018 Sep; 123(8):953-963. PubMed ID: 30355031
[TBL] [Abstract][Full Text] [Related]
13. CRISPR-CAS Replacing Antiviral Drugs against HIV: An Update.
Hashmat R; Yousaf MZ; Rahman Z; Anjum KM; Yaqoob A; Imran M
Crit Rev Eukaryot Gene Expr; 2020; 30(1):77-83. PubMed ID: 32421986
[TBL] [Abstract][Full Text] [Related]
14. Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex.
Saayman SM; Lazar DC; Scott TA; Hart JR; Takahashi M; Burnett JC; Planelles V; Morris KV; Weinberg MS
Mol Ther; 2016 Mar; 24(3):488-98. PubMed ID: 26581162
[TBL] [Abstract][Full Text] [Related]
15. Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study.
Kaminski R; Bella R; Yin C; Otte J; Ferrante P; Gendelman HE; Li H; Booze R; Gordon J; Hu W; Khalili K
Gene Ther; 2016 Aug; 23(8-9):690-5. PubMed ID: 27194423
[TBL] [Abstract][Full Text] [Related]
16. AAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9.
Li A; Tanner MR; Lee CM; Hurley AE; De Giorgi M; Jarrett KE; Davis TH; Doerfler AM; Bao G; Beeton C; Lagor WR
Mol Ther; 2020 Jun; 28(6):1432-1441. PubMed ID: 32348718
[TBL] [Abstract][Full Text] [Related]
17. CCR5 editing by Staphylococcus aureus Cas9 in human primary CD4
Xiao Q; Chen S; Wang Q; Liu Z; Liu S; Deng H; Hou W; Wu D; Xiong Y; Li J; Guo D
Retrovirology; 2019 Jun; 16(1):15. PubMed ID: 31186067
[TBL] [Abstract][Full Text] [Related]
18. CRISPR-Cas based antiviral strategies against HIV-1.
Wang G; Zhao N; Berkhout B; Das AT
Virus Res; 2018 Jan; 244():321-332. PubMed ID: 28760348
[TBL] [Abstract][Full Text] [Related]
19. The gRNA Vector Level Determines the Outcome of Systemic AAV CRISPR Therapy for Duchenne Muscular Dystrophy.
Wasala NB; Million ED; Watkins TB; Wasala LP; Han J; Yue Y; Lu B; Chen SJ; Hakim CH; Duan D
Hum Gene Ther; 2022 May; 33(9-10):518-528. PubMed ID: 35350865
[TBL] [Abstract][Full Text] [Related]
20. Genome modification of CXCR4 by Staphylococcus aureus Cas9 renders cells resistance to HIV-1 infection.
Wang Q; Chen S; Xiao Q; Liu Z; Liu S; Hou P; Zhou L; Hou W; Ho W; Li C; Wu L; Guo D
Retrovirology; 2017 Nov; 14(1):51. PubMed ID: 29141633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
